MGE 201
Alternative Names: MGE-201Latest Information Update: 12 Jan 2023
At a glance
- Originator Primera Therapeutics
- Class Gene therapies
- Mechanism of Action Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Mitochondrial disorders
Most Recent Events
- 12 Jan 2023 Primera Therapeutics plans preclinical trial in Mitochondrial disorders in 2H of 2024 (Primera Therapeutics pipeline, January 2023)
- 04 Jan 2023 Early research in Mitochondrial disorders in USA (Parenteral) Before January 2023 (Primera Therapeutics pipeline, January 2023)
- 04 Jan 2023 Primera Therapeutics plans to file IND application in Mitochondrial disorders in 1H of 2026 (Primera Therapeutics pipeline, January 2023)